Retatrutide

Semaglutide is a single GLP-1 agonist. Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide is a triple agonist, adding glucagon receptor activation to the mix. This third pathway increases energy expenditure, making it uniquely potent for weight loss compared to the others.

The most common side effects are gastrointestinal, like nausea and diarrhea. They are most pronounced when starting or increasing the dose. This is why a slow dose titration schedule, starting low and increasing every 4 weeks, is absolutely critical to allow your body to adapt and minimize these effects.

You'll likely feel the appetite suppression effects within the first week or two. However, significant weight loss is a gradual process. Clinical trials show the most dramatic results accumulate over months, with peak weight loss observed after nearly a year of consistent use.

It is still an investigational compound, but Phase 2 trials ran for 48 weeks, and Phase 3 trials are ongoing for even longer durations. The data so far suggests a safety profile consistent with other drugs in its class, but long-term effects beyond a couple of years are still being studied by its manufacturer.

Any significant caloric deficit can lead to the loss of both fat and lean mass. While Retatrutide primarily targets fat, preserving muscle requires conscious effort. It's essential to consume adequate protein (1.6-2.2g per kg of body weight) and incorporate resistance training during a Retatrutide research protocol to minimize muscle loss.